StonvexLoading…
StonvexStonvexStonvexCore line items from AMTM's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q3 2026 (Est.) Expected 2026-08-03 | Q2 2026 2026-04-03 | Q1 2026 2026-01-02 | Annual 2025 2025-10-03 | Q2 2025 2025-06-27 |
|---|---|---|---|---|---|
Revenue | $3.64B | $6.71B | $3.24B | $14.39B | $10.47B |
Operating Income | Not available | $289.00M | $138.00M | $480.00M | $345.00M |
Net Income | Not available | $98.00M | $44.00M | $66.00M | $26.00M |
EPS (Diluted) | $0.62 | $0.40 | $0.18 | $0.27 | $0.11 |
Total Assets | Not available | $11.17B | $11.20B | $11.46B | $11.81B |
Total Liabilities | Not available | $6.47B | $6.54B | $6.84B | $7.22B |
Cash & Equivalents | Not available | $428.00M | $247.00M | $437.00M | $738.00M |
Free Cash Flow OCF − CapEx | Not available | $78.00M | $-142.00M | $516.00M | $255.00M |
Shares Outstanding | Not available | 244.09M | 243.77M | 243.46M | 243.32M |